Nucleic acid constructs

By introducing frame sliding or translational motifs into nucleic acid constructs, combining self-cleaved peptides and attenuated signal peptide sequences, the problem of transgene expression regulation in gene therapy is solved, the fine control of transgene expression is achieved, and cytokine expression is reduced toxicity risk improves efficacy and safety.

CN119040361APending Publication Date: 2024-11-29AUTOLUS LIMIED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411105275.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-07-31
Filing Date
2019-07-31
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing gene therapy methods are difficult to effectively regulate the relative expression of multiple transgenes, especially in CAR-T cell therapy, the expression of cytokines such as IL-12 is difficult to predict and control, resulting in toxicity and side effects, and the prior art depends on Small molecule induces systems or internal ribosome entry sites, limiting the accuracy and safety of expression regulation.

Method used

Using frame sliding or translational motif technology, the expression of transgenes is controlled by introducing frame sliding motifs or translational motifs into nucleic acid constructs, so as to achieve fine regulation of the relative expression of transgenes, reduce the expression level of downstream transgenes, and The expression level is further optimized by combining the self-cleaved peptide and the attenuated signal peptide sequence.

Benefits of technology

Achieve predictable and deterministic regulation of transgene expression, significantly reduce the expression level of cytokines such as IL-12, reduce toxicity risks, improve efficacy and safety, and is suitable for CAR-T cell therapy and other gene therapy applications .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004990578070000181
    Figure BDA0004990578070000181
  • Figure BDA0004990578070000261
    Figure BDA0004990578070000261
  • Figure HDA0004990578080000011
    Figure HDA0004990578080000011
Patent Text Reader

Abstract

The present invention provides a nucleic acid construct comprising: a first nucleotide sequence of interest (NOI1); a frame sliding motif or a translation continuous reading motif (FSM / TRM); and a second nucleotide sequence of interest (NOI2). The invention also provides vectors and cells expressing such constructs. The invention also provides a method of modulating the relative expression of two transgenes in a nucleic acid construct, the method comprising the step of including a frame sliding motif or a translated contiguous reading motif between the two transgenes to reduce the expression of downstream transgenes.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application based on a patent application with an application date of July 31, 2019, a priority date of July 31, 2018, an application number of 201980047231.9, and an invention name of “Nucleic Acid Construct”. Field of the Invention

[0002] The present invention relates to constructs and methods for modulating the relative expression of transgenes. Background of the Invention

[0004] Expression of multiple transgenes

[0005] Gene therapy involves the modification of cells to express biomolecules to treat or correct pathological conditions. Achieving physiologically or therapeutically relevant levels of biomolecules is key to successful gene therapy.

[0006] Current methods for regulating gene expression generally rely on modifying promoter regions to increase or decrease transcription rates or inserting regulatory elements therein to make their expression inducible through the action of engineered transcription factors and small molecules.

[0007] Gene therapy approaches often involve the expression of more than one transgene. Transducing cells with multiple vectors to produce multiple products is difficult, expensive, and unpredictable. Therefore, various methods have been developed to allow co-expression of two proteins from a single vector (see Figure 1 ).

[0008] Initial attempts used two different promoters in the same expression cassette, which would produce two independent transcripts, each encoding an independent protein. This is a difficult approach for a number of reasons. A key issue is "promoter interference," where one promoter becomes dominant and causes silencing of the second. Additionally, different promoters operate differently in different cellular environments, making it difficult to achieve consistent "regulation" of the relative expression of each transgene.

[0009] An alternative approach is to use an internal ribosome entry sequence (IRES). Here, a single transcript is generated. The IRES sequence in the transcript is located between the open reading frames of the two transgenes and mimics the mRNA cap structure. Thus, the ribosomes start translation at the 5' cap or IRES, resulting in the expression of two independent proteins. A key limitation of this approach is that relative expression cannot be controlled. The 3' transcript is usually expressed less than the 5' transcript, but the expression ratio is difficult to predict and adjust.

[0010] Another approach has been developed based on the characterization of the role of the foot-and-mouth disease virus (FMDV) 2A peptide in allowing FMDV (and related viruses) to express multiple proteins from a single open reading frame (ORF) (Donnelly et al; J. Gen. Virol.; 82, 1027–1041 (2001)). The 2A peptide (and homologues) are cleaved with extremely high efficiency immediately after ORF translation, allowing multiple peptides to be expressed from a single ORF. The use of self-cleaving peptides such as the 2A peptide results in expression of transgenes in a 1:1 ratio.

[0011] WO2016 / 174409 describes the use of altered signal peptides to alter the ratio of transgene expression in nucleic acid constructs. In this system, mutations are introduced into the signal peptide motif of, for example, a type I transmembrane protein to reduce the efficacy of transport to the cell surface. This approach can reduce cell surface expression levels by about 10 times compared to the wild-type signal peptide motif.

[0012] However, this strategy is only applicable to reducing the expression of cell surface proteins because it works by reducing the trafficking of proteins to the cell surface. In addition, a 10-fold reduction in expression may not be sufficient for some applications, such as the expression of toxic compounds, where overexpression can lead to host cell death.

[0013] Therefore, alternative methods of altering the relative expression of two or more transgenes in a cell that are not associated with these limitations are needed.

[0014] Chimeric Antigen Receptor (CAR)

[0015] Chimeric antigen receptor T cell (CAR-T cell) therapy redirects cytolytic T cells to target tumor cells by expressing chimeric antigen receptors (CARs) that recognize tumor-specific antigens on the cell surface. Chimeric antigen receptors consist of antibody or ligand binding motifs, spacer domains, and transmembrane domains, which are fused to the intracellular signaling domain of the CD3ζ chain of the T cell receptor (TCR). Signaling domains from co-receptors such as CD28, OX40, or 4-1BB can also be included in CAR 1 together with the CD3ζ signaling domain.

[0016] CAR-T cell therapy has been shown to be an effective treatment for hematological malignancies such as B-cell leukemia, achieving impressive response rates. However, CAR-T cell therapy has not been as successful in the treatment of solid tumors, with a number of factors compounded to limit the activity of CAR-T cells. These factors include the expression of immunosuppressive ligands such as PD-L1, the secretion of cytokines that inhibit favorable inflammatory responses, the expression of ligands that induce tumor cell apoptosis and nutrient depletion. To overcome the immunosuppressive tumor microenvironment, CAR-T cells are engineered to express molecules that block immunosuppressive signaling or enable T cells to survive in the hostile tumor microenvironment.

[0017] Cytokines that enhance inflammatory responses can improve the efficacy of CAR-T cell therapy. These cytokines include IL-7, IL-12, IL15, IL-17A, IL-18, and IL-21, which have been shown to enhance CAR-T cell responses when provided exogenously or released during CAR T cell therapy.

[0018] IL-12 is a potent immunoregulatory cytokine that is normally secreted by phagocytes and dendritic cells in response to: pathogens; T cell signaling and natural killer (NK) cell signaling; and extracellular matrix components. CAR-T cells have been engineered to express IL-12 either constitutively or from an inducible promoter, which has been shown to improve the efficacy of CAR-T cell therapy when targeting solid tumors. IL-12 is systemically toxic, so CAR T cells or other immune cells have been engineered to release IL-12 into the tumor microenvironment1. However, genetically modified T cell IL-12 secretion can result in highly toxic systemic levels.

[0019] Although the expression of cytokines, chemokines, or toxins can improve the efficacy of CAR-T cell therapy, the secretion of these biomolecules must be strictly regulated to limit their toxicity to safe levels that provide therapeutic benefits and minimal side effects. This can be achieved by inserting or deleting cis-acting sequences to obtain the desired transcription level or introducing inducible elements into the promoter region to regulate the rate of transcription of genes from the promoter region. Notable inducible promoter systems include the tetracycline shut-off (tet-off) system and the tetracycline shut-off (tet-off) system, which utilize a tetracycline response element (TRE) with an engineered form of the tetracycline repressor protein (TetR), which binds to a 19 bp nucleotide sequence of the TRE2. In the tetracycline shut-off system, TetR is fused to the transactivation domain of viron protein 16 (VP16) of the herpes simplex virus to generate the tetracycline transactivator (tTA). In the absence of tetracycline, tTA binds to the TRE in the promoter region and enhances gene transcription; conversely, in the presence of tetracycline, tTA is unable to bind to the TRE and transcription does not occur. Mutations in the TetR domain in tTA render it dependent on tetracycline to bind to the TRE, thereby generating a reverse tTA (rtTA) and tetracycline on the system. In the presence of tetracycline, rtTA is able to bind to the TRE and stimulate transcription, but not in its absence. Although the tetracycline-inducible system is able to control transgene expression, it relies on the use of small molecules, the insertion of a TRE in the promoter sequence, and the expression of tTA or rtTA, which places a heavy burden on the cell.

[0020] An alternative method to control gene expression is to use an internal ribosome entry site (IRES). As described above, the IRES is placed downstream of the main transgene and promotes the constitutive expression of other transgenes, which are usually lower than the main transgene. This approach has been used to constitutively express IL-12 in CAR-T cells in an attempt to enhance the immune response and avoid pre-treatment of the host before infusion of CAR-T cells. However, the expression level of IL-12 is unpredictable and can still be toxic in vivo.

[0021] Therefore, there is a need for alternative methods for co-expressing chimeric antigen receptors with molecules such as cytokines, chemokines or toxins that are not associated with the above-mentioned disadvantages. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 : Method for expressing different proteins from the same vector

[0023] (a) Two different promoters within the same expression cassette produce two different transcripts, each producing an independent protein. (b) The use of an internal ribosome entry sequence (IRES) produces a single transcript that is translated into two independent proteins. (c) The use of the FMDV 2A peptide produces a single transcript and a single polyprotein that is rapidly cleaved into two separate proteins.

[0024] Figure 2 : Frame-slip motif and construct design

[0025] (A) illustrates a diagram of a frame sliding motif, in which a series of seven uridines are inserted into the transgenic sequence, thereby promoting frame sliding. Frame sliding causes the alternative reading frame, usually in the -1 direction, to continue transcription / translation and generate functional protein. (B) Construct structure showing the location of the transgene, frame sliding motif (SLIP) and 2A self-cleaving peptide sequence. (C) Flow cytometric analysis of SupT1 cells transduced with constructs containing the RQR8 sorting marker, followed by a control sequence (6xU) or a frame sliding motif (7xU) and a CD22-CD19 chimeric protein consisting of the extracellular domain of CD22 fused to the transmembrane and truncated intracellular domains of CD19. The introduction of the frame sliding motif resulted in a significant reduction in the expression of the CD22-CD19 chimera, while similar levels of the RQR8 sorting marker were observed.

[0026] Figure 3 : Translation read-through motifs and construct design.

[0027] (A) Examples of known translation read-through motifs. (BG) Structures of translation read-through motif constructs. (B) Translation read-through constructs consisting of two transgenes, where the translation read-through motif is located 3' and 2A self-cleaving peptide sequence of the first transgene and 5' of transgene 2. Expression of transgene 1 will be significantly higher than transgene 2. (B') Double stop codon translation read-through construct, where two stop codons are incorporated into the translation read-through motif to reduce expression levels to levels lower than those obtained using a single stop codon. (C) Universal translation read-through construct, which consists of a translation read-through motif flanked by two 2A self-cleaving peptide sequences. This construct mitigates sequence-dependent effects that can lead to unpredictable translation read-through levels. (D) Combination scheme, where the translation read-through motif is combined with an attenuated signal peptide sequence to further reduce the expression level of transgene 2. (E and E') Composite translation read-through motifs, where multiple motifs are placed in tandem to produce a cascade of transgene expression reduction. (E) Multiple transgenes are expressed from a single expression cassette using a translation read-through motif and a 2A self-cleaving peptide sequence. (E') A self-cleaving peptide sequence is used to separate the 5' translation read-through motif of transgene 2. (F and F') Functional translation read-through constructs. (F) Secretion of antigen binding domains (scFv / VHH) and functional CARs can be achieved by placing the translation read-through motif at the 3' of the CAR spacer domain. Functional read-through leads to the expression of functional CARs, while termination of translation at the stop codon produces secreted antibodies. (F') A combination of first-generation CARs, second-generation CARs, and third-generation CARs can be produced by placing the translation read-through motif at the 3' of the first intracellular domain (CD3ζ intracellular domain or co-receptor intracellular domain). Functional translation read-through will switch expression from a first-generation CAR to a second-generation or third-generation CAR.

[0028] Figure 4: Comparison of attenuated signal peptide and translational read-through motif strategies for controlling expression of CD22-CD19 chimeras.

[0029] ( Figure 4A ) Flow cytometric analysis of HEK293T cells transfected with constructs encoding the RQQ8 sorting marker and the CD22-CD19 chimera. Signal peptide mutants (row 1), translation read-through motif constructs (rows 2 and 3), and double stop codon translation read-through motif (row 4). Expression of the CD22-CD19 chimera was reduced in the lysine 11 signal peptide mutant (L11K mutation) compared to the wild-type signal peptide. When the stop-CUAG and stop-CAAUUA translation read-through motifs were placed 5' to the CD22-CD19 transgene, they produced similar results, with both motifs reducing the expression level of the chimera to approximately 2% or less of the RQR8 sorting marker. Lower CD22-CD19 chimera expression levels were obtained using the double stop codon translation read-through motif (row 4). ( Figure 4B ) Quantification of mean fluorescence intensity of CD22-CD19 chimeras on the surface of HEK293T cells transfected with attenuated signal peptide mutants compared to translation read-through constructs. Substantially lower levels of CD22-CD19 chimeras were obtained using translation read-through constructs compared to attenuated signal peptide mutants.

[0030] Figure 5 : Tandem translation read-through motifs

[0031] A) the figure of the construct produced by placing the stop codon and the translation read-through motif in series.For simplicity, only four examples are shown, which show the structure of the construct with the translation read-through motif in series.Cell surface markers, i.e., the HA epitope presented on the CD8a stem (CD8a stalk), are always located in the first position in the expression cassette, followed by the Clover3 or EBFP in series with different coding sequences, which are separated by self-cleaving peptide sequences (2A).Two control constructs were cloned, in which the stop codon was replaced by UGG (encoding tryptophan), and the mClover or EBFP in series were located in the second or third position.For the construct with the translation read-through motif in series, all three stop codons (UGA, UAG and UAA) were tested, and the translation read-through motif used was CUAG.The same stop codon was used in two positions. 1,2,3-D-1,4-D-1,6-D-1,8-D-1,9-D-1,10-D-11,12-D-13,14-D-15-D-16,16-D-17,18-D-19,19-D-1 ...

[0032] Figure 6 : Controlled expression of human flexi-IL-12 downstream of a translational read-through motif

[0033] A) A diagram showing the structure of the construct, in which a human flexi-IL-12 consisting of a fusion between IL-12α (p35) and IL-12β (p40) subunits is placed downstream of the sorting marker RQR8, where a self-cleaving peptide promotes the expression of both proteins. All three stop codons were tested with the translation read-through motif CAAUUA. B) Representative flow cytometry images of PBMCs transduced with the construct and stained with antibodies against CD3ε and RQR8. C) Quantification of IL-12 secreted from transduced PBMCs at 24 hours, 48 ​​hours, and 72 hours after determining the transduction efficiency. The results show that IL-12 secretion from the translation read-through construct is significantly reduced.

[0034] Figure 7 : Controlled expression of murine IL-12 downstream of a translational read-through motif

[0035] A) Diagram of a tricistronic construct with a suicide gene (RapaCasp9), a cell surface marker Thy1.1, and mouse flexi-IL-12. Mouse flexi-IL-12 levels are regulated by internal ribosome entry sites (IRES), attenuated signal peptide motifs, or translation read-through motifs. B) Representative flow cytometry images of BalbC splenocytes transduced with constructs and stained with antibodies against CD3ε and Thy1.1. C) Quantification of IL-12 levels secreted from transduced splenocytes by ELISA. D) Supernatant from transduced splenocytes was used to restimulate activated splenocytes. The presence of IFNg in the supernatant from restimulation was analyzed by ELISA. Importantly, these results indicate that supernatants of splenocytes transduced with translation read-through motifs can cause IFNγ secretion from restimulated splenocytes.

[0036] Figure 8 : Toxicity testing of translational read-through IL-12 constructs

[0037] A) Splenocytes were co-transduced with a previously described construct encoding RapaCasp6, Thy1.1 and IL-12 and a second construct comprising truncated mouse CD34 (mudCD34), firefly luciferase (FLuc) and anti-GD2 chimeric antigen receptor (CAR). Transduced splenocytes were stained with antibodies against CD34 and Thy1.1, and flow cytometry was performed to determine transduction efficiency. B) Mice were injected with transduced splenocytes and sacrificed after 15 days and the spleen was removed. Splenomegaly was observed only in mice injected with splenocytes transduced with constitutively expressed IL-12 (labeled as group 2A).

[0038] Fig. 9 : Flow cytometric analysis of splenocytes

[0039] A) Splenocytes from sacrificed mice were stained with antibodies against CD11b, CD3, CD4, CD8 and CD19 and analyzed by flow cytometry. The gating strategy used is shown. BF) The presence of CD11b + (macrophages), CD3 + (T cells), CD4 + (helper T cells), CD8 + (cytotoxic T cells) and C19 + The percentage of (B cells). The number of macrophages and T cells in the spleen of mice injected with splenocytes transduced with constructs constitutively expressing IL-12 or constructs from IRES increased. A decrease in the number of B cells was observed in mice with splenocytes constitutively expressing IL-12. SUMMARY OF THE INVENTION

[0041] The present inventors have developed a system that uses frame slipping or translational read-through as a means of regulating transgene expression. In particular, this system can be used to control the relative expression of two or more transgenes expressed from a single mRNA transcript.

[0042] Therefore, in a first aspect, the present invention provides a nucleic acid construct comprising: a first nucleotide sequence of interest (NOI1); a frame slipping motif or a translation read-through motif (FSM / TRM); and a second nucleotide sequence of interest (NOI2).

[0043] The nucleic acid construct may further comprise a nucleotide sequence encoding a cleavage site (CL) so that NOI1 and NOI2 are expressed as separate proteins.

[0044] The nucleic acid construct may comprise the following structures:

[0045] NOI1–FSM / TRM-CL–NOI2 or NOI1-CL-FSM / TRM-NOI2.

[0046] In particular, the nucleic acid construct comprises the following structure:

[0047] NOI1–CL-FSM–NOI2; or

[0048] NOI1-TRM-CL-NOI2.

[0049] The nucleic acid construct may contain more than two target nucleotide sequences. For example, the nucleic acid construct may have the following structure:

[0050] NOI1–FSM1 / TRM1-CL1–NOI2-FSM2 / TRM2-CL2-NOI3, or

[0051] NOI1–CL1-FSM1 / TRM1–NOI2-CL2-FSM2 / TRM2-NOI3

[0052] in:

[0053] NOI1, NOI2, and NOI3 are target nucleotide sequences;

[0054] FSM1 / TRM1 and FSM2 / TRM2 may be the same or different and may be frame-slipping motifs or translation read-through motifs; and

[0055] CL1 and CL2 may be the same or different, and are nucleic acid sequences encoding respective cleavage sites.

[0056] The frame slipping motif (FSM) may comprise repeats of uracil, thymine or guanine bases, for example the sequence UUUUUUU (SEQ ID No. 1).

[0057] The frame slip motif may also include a stop codon. For example, the FSM may include one of the following sequences:

[0058] UUUUUUUGA (SEQ ID NO. 2)

[0059] UUUUUUUAG (SEQ ID NO. 3)

[0060] UUUUUUUUAA (SEQ ID NO. 4).

[0061] A translation read-through motif (TRM) may comprise the sequence STOP-CUAG or STOP-CAAUUA, where "STOP" is a stop codon. For example, a translation read-through motif may comprise one of the following sequences:

[0062] UGA-CUAG (SEQ ID No. 5)

[0063] UAG-CUAG (SEQ ID No. 6)

[0064] UAA-CUAG (SEQ ID No. 7)

[0065] UGA-CAAUUA (SEQ ID No. 8)

[0066] UAG-CAAUUA (SEQ ID No. 9)

[0067] UAA-CAAUUA (SEQ ID No. 10)

[0068] A nucleic acid construct comprising a translation read-through motif may comprise two adjacent TRMs which may be the same or different.

[0069] The nucleic acid construct comprising a translation read-through motif may comprise two nucleic acid sequences each encoding a cleavage site. The TRM may be located between the two cleavage site encoding sequences, or two TRMs may be present, each TRM being located upstream of the cleavage site.

[0070] A nucleic acid construct comprising a translation read-through motif may comprise an attenuated or inefficient signal peptide located upstream of the second (or subsequent) nucleotide of interest.

[0071] The nucleic acid construct comprising a translation read-through motif may have one of the following sequences:

[0072] NOI1–TRM-CL–NOI2

[0073] NOI1-TRM1-TRM2-CL-NOI2

[0074] NOI1-CL1-TRM-CL2-NOI2

[0075] NOI1-TRM-CL-SP-NOI2

[0076] NOI1–TRM1-CL1–NOI2-TRM2-CL2-NOI3

[0077] NOI1–TRM1-CL1-TRM2-CL2–NOI2

[0078] in:

[0079] TRM1 and TRM2 can be the same or different and are the first translation read-through motif and the second translation read-through motif;

[0080] CL1 and CL2 may be the same or different, and are a first nucleic acid sequence and a second nucleic acid sequence, respectively encoding a cleavage site;

[0081] SP is a weakened signal peptide; and

[0082] NOI3 is the third target nucleotide sequence.

[0083] The cleavage site may, for example, comprise a self-cleaving peptide, a furin cleavage site, or a tobacco etch virus cleavage site.

[0084] The cleavage site may, for example, comprise a 2A self-cleaving peptide or a 2A-like peptide from foot-and-mouth virus or cardiovirus.

[0085] The second (or subsequent) nucleotide of interest may encode a cytokine, chemokine, or toxin.

[0086] When a nucleic acid construct is expressed in a cell, two products can be produced:

[0087] a) a first product encoded only by NOI1; and

[0088] b) A second product encoded by NOI1 and NOI2, which is produced when frame slippage or translational read-through occurs.

[0089] In this embodiment, the second product can be a chimeric antigen receptor (CAR) and the first product can be a truncated form of the CAR that is unable to induce CAR-mediated cell signaling.

[0090] Alternatively, the first product can be a chimeric antigen receptor (CAR, i.e., a first generation CAR) comprising an intracellular signaling domain, and the second product is a CAR (i.e., a second or third generation CAR) comprising an intracellular signaling domain and one or more co-stimulatory domains.

[0091] In a second aspect, the present invention provides a vector comprising the nucleic acid construct according to the first aspect of the present invention.

[0092] The vector may, for example, be a retroviral vector or a lentiviral vector.

[0093] In a third aspect, the present invention provides a cell comprising the nucleic acid construct according to the first aspect of the invention or the vector according to the second aspect of the invention.

[0094] In a fourth aspect, the present invention provides a method for preparing a cell according to the third aspect of the present invention, comprising the step of introducing a nucleic acid construct according to the first aspect of the present invention or a vector according to the second aspect of the present invention into a cell.

[0095] In a fifth aspect, the present invention provides a method for regulating the relative expression of two transgenes in a nucleic acid construct, the method comprising the following steps: introducing a frame slip motif or a translation read-through motif between the two transgenes to reduce the expression of the downstream transgene.

[0096] A clear advantage of using frame slipping or translational read-through as a means of controlling transgene expression is that broad expression can be achieved, and where two transgenes are expressed, the expression level of the second transgene can be reduced to less than 1% of the first. This is significantly lower than the levels achievable using altered signal peptides and makes this technology useful for expressing proteins such as toxic compounds where extremely low expression levels are necessary.

[0097] The use of frame slipping or translational read-through allows the transgene to be expressed at a predictable and defined rate. The expression level of the transgene can also be modulated by using different frame slipping motifs or read-through motifs.

[0098] This system can be used to control the expression of any transgene and is not limited to the expression of cell surface proteins.

[0099] This application also relates to the following implementation schemes:

[0100] 1. A nucleic acid construct comprising: a first target nucleotide sequence (NOI1); a frame slip motif (FSM) or a translation read-through motif (TRM); and a second target nucleotide sequence (NOI2).

[0101] 2. The nucleic acid construct according to embodiment 1 further comprises a nucleotide sequence encoding a cleavage site (CL), so that NOI1 and NOI2 are expressed as independent proteins.

[0102] 3. The nucleic acid construct according to embodiment 2 has the following structure:

[0103] NOI1-CL-FSM-NOI2; or

[0104] NOI1-TRM-CL-NOI2.

[0105] 4. The nucleic acid construct according to any one of the preceding embodiments, comprising a frame sliding motif (FSM), which comprises repeats of uracil, thymine or guanine bases.

[0106] 5. The nucleic acid construct of embodiment 4, wherein the FSM comprises the sequence UUUUUUU (SEQ ID No. 1).

[0107] 6. The nucleic acid construct of embodiment 4 or 5, wherein the FSM further comprises a stop codon.

[0108] 7. The nucleic acid construct according to embodiment 6, wherein the FSM comprises one of the following sequences:

[0109] UUUUUUUGA (SEQ ID NO. 2)

[0110] UUUUUUUAG (SEQ ID NO. 3)

[0111] UUUUUUUUAA (SEQ ID NO. 4).

[0112] 8. A nucleic acid construct according to any one of embodiments 1 to 3, comprising a translation read-through motif (TRM), which comprises the sequence STOP-CUAG or STOP-CAAUUA, wherein "STOP" is a stop codon.

[0113] 9. The nucleic acid construct of embodiment 8, wherein the translation read-through motif comprises one of the following sequences:

[0114] UGA-CUAG (SEQ ID No. 5)

[0115] UAG-CUAG (SEQ ID No. 6)

[0116] UAA-CUAG (SEQ ID No. 7)

[0117] UGA-CAAUUA (SEQ ID No. 8)

[0118] UAG-CAAUUA (SEQ ID No. 9)

[0119] UAA-CAAUUA (SEQ ID No. 10).

[0120] 10. The nucleic acid construct according to embodiment 8 or 9 has the following structure:

[0121] NOI1-TRM-CL-NOI2

[0122] NOI1-TRM1-TRM2-CL-NOI2

[0123] NOI1-CL1-TRM-CL2-NOI2

[0124] NOI1-TRM-CL-SP-NOI2

[0125] NOI1-TRM1-CL1-NOI2-TRM2-CL2-NOI3

[0126] NOI1-TRM1-CL1-TRM2-CL2-NOI2

[0127] in:

[0128] TRM1 and TRM2 can be the same or different and are the first translation read-through motif and the second translation read-through motif;

[0129] CL1 and CL2 may be the same or different, and are a first nucleic acid sequence and a second nucleic acid sequence, respectively encoding a cleavage site;

[0130] SP is a weakened signal peptide; and

[0131] NOI3 is the third target nucleotide sequence.

[0132] 11. The nucleic acid construct of embodiments 2 to 10, wherein the cleavage site comprises a self-cleaving peptide, a furin cleavage site, or a tobacco etch virus cleavage site.

[0133] 12. A nucleic acid construct according to embodiment 11, wherein the cleavage site comprises a 2A self-cleaving peptide from foot-and-mouth virus or cardiovirus, or a 2A-like peptide.

[0134] 13. The nucleic acid construct according to any one of the preceding embodiments, wherein NOI2 encodes a cytokine, a chemokine or a toxin.

[0135] 14. The nucleic acid construct according to embodiment 1 is capable of producing two products when expressed in a cell:

[0136] a) a first product encoded only by NOI1; and

[0137] b) A second product encoded by NOI1 and NOI2, which is produced when frame slippage or translational read-through occurs.

[0138] 15. A nucleic acid construct according to embodiment 14, wherein the second product is a chimeric antigen receptor (CAR) and the first product is a truncated form of the CAR that is unable to induce CAR-mediated cell signaling.

[0139] 16. A nucleic acid construct according to embodiment 14, wherein the first product is a chimeric antigen receptor (CAR) comprising an intracellular signaling domain, and the second product is a CAR comprising an intracellular signaling domain and one or more co-stimulatory domains.

[0140] 17. A vector comprising the nucleic acid construct according to any one of the preceding embodiments.

[0141] 18. The retroviral vector or lentiviral vector according to embodiment 17.

[0142] 19. A cell comprising the nucleic acid construct according to any one of embodiments 1 to 16 or the vector according to embodiment 17 or 19.

[0143] 20. A method for preparing the cell according to embodiment 19, comprising the step of introducing the nucleic acid construct according to any one of embodiments 1 to 16 or the vector according to embodiment 17 or 18 into the cell.

[0144] 21. A method for regulating the relative expression of two transgenes in a nucleic acid construct, comprising the step of including a frame slip motif or a translation read-through motif between the two transgenes to reduce expression of the downstream transgene. DETAILED DESCRIPTION OF THE INVENTION

[0146] The present invention relates to nucleic acid constructs comprising a motif that reduces transgene expression, such as a frame-slipping motif or a translational read-through motif.

[0147] Frame Slide

[0148] During transcription, RNA polymerase catalyzes the incorporation of nucleotides into a growing RNA chain based on complementarity with a DNA template. However, when RNA polymerase encounters a stretch of repeated bases, slippage or "slippage" occurs. Transcription slippage is used in nature, for example, to regulate the expression of the pyrBI and codBA operons in Escherichia coli, the P gene in Paramyxovirus, and the decoding of the cellular dnaX gene in Thermus thermophilus.

[0149] When RNA polymerase slips, it can result in the synthesis of mRNA encoding an alternative reading frame due to the lack of one (or possibly two) repeat bases.

[0150] The nucleic acid constructs of the invention may comprise a transcription frame slippage site, such that transcription of a downstream transgene occurs only when there is slippage of the RNA polymerase, thereby producing mRNA encoding an alternative reading frame.

[0151] The translation of mRNA sequences into proteins is a complex process involving the orchestration of ribosomes, initiation and elongation factors, aminoacyl transfer RNA (aa-tRNA), aminoacyl tRNA synthetases, and release factors. Translation begins when multiple factors bind to the 5' end of the mRNA, which then leads to the recruitment of the 40S ribosome and scanning of the mRNA. When the complex of the initiation factor and the 40S ribosome encounters a codon (triplet of nucleotides) encoding the amino acid methionine (AUG codon), the 60S ribosome is recruited, and polypeptide synthesis begins with the pairing of the cognate tRNA loaded with the appropriate amino acid. The initiation of translation can occur at other start codons besides AUG, but AUG is the most commonly used start codon. The elongation of the polypeptide occurs in a cyclic manner, in which tRNA binds to its cognate codon, a peptide bond is formed between the newly added amino acid and the extended polypeptide, and the polypeptide is translocated to expose the next codon.

[0152] During translation, ribosome pausing may occur, where the ribosome is stalled at a specific codon. Ribosome pausing can promote mRNA degradation through the nucleocytic pathway, or can induce slipping in the -1 or -2 direction. Repeated sequences such as UUUUUUA within mRNA are known to cause translation frame slipping, and this sequence is present at the 3' end of the group-specific antigen gene (gag) and polymerase (pol) gene of the human immunodeficiency virus (HIV). Translation frame slipping of the HIV gag / pol gene by -1 results in the expression of the Gag-Pol polyprotein.

[0153] The nucleic acid constructs of the invention may comprise a translation frame slipping site, such that translation of the downstream transcript occurs only when there is a ribosomal frame slip.

[0154] A frame slip site may include a stretch of bases of the same type.

[0155] The frame-slipping motif can be placed upstream and / or downstream of the cleavage site in the nucleic acid construct.The frame-slipping motif can be located between the first transgene and the second transgene in the nucleic acid construct.

[0156] The frame-slipping motif can be used alone. In this embodiment, a second transgene can be placed out of frame downstream of the frame-slipping site, such that transcription or translation of the second transgene requires the frame-slipping.

[0157] The motif may for example comprise a stretch of 5, 7, 8, 10 or 11 bases. The site may for example comprise repeated uracil, adenine or guanine bases. The site may for example comprise a sequence as shown in SEQ ID No.1.

[0158] UUUUUUU (SEQ ID No. 1).

[0159] Alternatively, the frame slipping site can be used in combination with a stop codon. In this embodiment, the stop codon is located downstream of the frame slipping site in a manner consistent with the reading frame, so that frame slipping is required to ignore the stop codon.

[0160] The stop codon may be UGA, UAG or UAA. The frame slipping site may comprise a repeat of a uracil, adenine or guanine base in multiples of three, such as a repeat of 3, 6, or 9 uracil, adenine or guanine bases.

[0161] Examples of frame slip site / stop codon combinations are shown as SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 4.

[0162] UUUUUUUGA (SEQ ID NO. 2)

[0163] UUUUUUUAG (SEQ ID NO. 3)

[0164] UUUUUUUUAA (SEQ ID NO. 4).

[0165] Translation Link

[0166] Translation terminates when the ribosome encounters a UGA, UAG, or UAA stop codon. At this point, release factors recognize the stop codon and promote dissociation and recycling of the ribosome. Due to competition between release factors and nearby cognate tRNAs, translation termination usually occurs with high fidelity, accompanied by recoding of the stop codon, while continued elongation of the polypeptide occurs only 0.1% of the time. However, increased levels of recoded stop codons leading to translational readthrough have been reported in certain genes. In some cases, this has led to the production of longer polypeptides with additional functional motifs, a process called functional readthrough.

[0167] Translation readthrough occurs when release factor 1 (RF1) fails to recognize a stop codon and a nearby cognate aa-tRNA inserts an amino acid into the growing polypeptide, thereby suppressing the stop codon. The local concentrations of release factors and aa-tRNA influence the level of stop codon suppression and translation readthrough, with low concentrations of release factors promoting translation readthrough. In mammals, suppression of the UAG stop codon results in the insertion of a tryptophan, arginine, or cysteine ​​residue.

[0168] One of the earliest known examples of stop codon suppression was in the rabbit β-globin gene, where translational readthrough resulted in the addition of 22 amino acids to the C-terminus of the protein3.

[0169] The frequency of translation read-through depends on several factors, including: 1) the stop codon used (UGA, UAG, or UAA); 2) the sequences immediately flanking the stop codon, with the six nucleotides upstream and downstream of the stop codon being particularly important; and 3) the presence of cis-acting sequences at the 3' end of the mRNA.

[0170] The termination efficiency of the three stop codons varies, with UAA being the strongest stop codon and UGA being the weakest, and the ranking of termination efficiency is defined as UAA>UAG>UGA. Therefore, the UGA stop codon shows the highest level of translation read-through, while the UAA stop codon shows the lowest level of translation read-through.

[0171] Sequence analysis of genes that exhibit translational readthrough has identified at least two different motifs that promote stop codon suppression and continued translation: STOP-CUAG and STOP-CAAUUA (where STOP can be UGA, UAG, or UAA). The level of translational readthrough depends on the stop codon used: UGA supports the highest level of translational readthrough, and the levels of readthrough obtained from UAG and UAA stop codons gradually decrease, so that the overall ranking of readthrough is UGA>UAG>UAA.

[0172] The nucleic acid construct of the present invention may comprise one of the sequences shown in SEQ ID No.5 to SEQ ID No.10.

[0173] UGACUAG (SEQ ID No. 5)

[0174] UAGCUAG (SEQ ID No. 6)

[0175] UAACUAG (SEQ ID No. 7)

[0176] UGACAAUUA (SEQ ID No. 8)

[0177] UAGCAAUUA (SEQ ID No. 9)

[0178] UAACAAUUA (SEQ ID No. 10)

[0179] The translation read-through site can be located between the first transgene and the second transgene in the nucleic acid construct. The translation read-through site can be placed upstream and / or downstream of the cleavage site in the nucleic acid construct. The translation read-through site can be located on both sides of the cleavage site ( Figure 3 C). Two or more may be used, for example, placed next to each other ( Figure 3 B') or translation read-through sites on either side of the cleavage site (Figure E').

[0180] To further reduce the expression level of downstream transgenes, multiple stop codons can be inserted 5' to the translation read-through motif. Figure 2 B). An exemplary multiple stop codon translation read-through motif is shown as SEQ ID NO. 11, wherein two UGA stop codons are located 5' to the CUAG ​​read-through motif.

[0181] UGAUGACUAG (SEQ ID No. 11).

[0182] When the nucleic acid construct contains more than two transgenes, a composite translational read-through motif can be placed in tandem 5' to the sequence encoding the cleavage site. This allows multiple transgenes to be expressed at different ratios. With each additional read-through motif, the expression level should be reduced 10 to 50 fold relative to the upstream transgene.

[0183] A nucleic acid construct having a composite translation read-through motif may have the following structure:

[0184] NOI1-TRM1-CL1-NOI2-TRM2-CL2-NOI3

[0185] A read-through site can be placed within the coding sequence so that two versions of the protein are obtained: a short version obtained by translating the transcript up to the read-through site (i.e., no read-through occurs) and a long version obtained by translating outside the transcript and downstream of the read-through site (where read-through occurs). Examples of such arrangements are Figure 3 F and Figure 3 F' is shown.

[0186] Altered signal peptide

[0187] Although the translation read-through motif significantly reduces transgene expression, in some cases it may be necessary to further reduce expression levels. For type I transmembrane and secreted proteins, further reductions in expression can be achieved by combining the translation read-through motif with an altered signal peptide sequence. This approach is suitable for type I transmembrane proteins and secreted proteins that have a signal peptide sequence. In this case, the altered signal peptide and the second transgene are located 3'(4') to the translation read-through motif and the self-cleaving peptide sequence. Figure 3 D).

[0188] A signal peptide is a short peptide, usually 5-30 amino acids long, present at the N-terminus of most newly synthesized proteins destined for the secretory pathway. These proteins include those that are within certain organelles (e.g., the endoplasmic reticulum, the Golgi apparatus, or endosomes), secreted from the cell, and transmembrane proteins.

[0189] Signal peptides usually contain a core sequence, which is a long stretch of hydrophobic amino acids with a tendency to form a single alpha-helix. The signal peptide may begin with a short stretch of positively charged amino acids, which helps to enforce the correct topology of the polypeptide during translocation. At the end of the signal peptide, there is typically a stretch of amino acids that is recognized and cleaved by a signal peptidase. The signal peptidase may cleave during or after translocation to generate a free signal peptide and a mature protein. The free signal peptide is then digested by a specific protease.

[0190] The signal peptide is usually located at the amino terminus of the molecule, although some carboxy-terminal signal peptides are known.

[0191] Altered signal peptides are described in detail in WO2016 / 174409, which is incorporated herein by reference. The altered signal peptide may comprise one or more mutations, such as substitutions or deletions, such that it has fewer hydrophobic amino acids than the wild-type signal peptide from which it is derived. The term "wild-type" refers to the sequence of a signal peptide that is present in the native protein from which it is derived.

[0192] When a nucleic acid construct comprises two transgenes both encoding transmembrane proteins, the protein encoded by the downstream transgene (which has a lower relative expression) may comprise fewer hydrophobic amino acids than the protein encoded by the upstream transgene (which has a higher relative expression).

[0193] The hydrophobic amino acid mutated to alter the efficiency of the signal peptide may be: alanine (A); valine (V); isoleucine (I); leucine (L); methionine (M); phenylalanine (P); tyrosine (Y); or tryptophan (W).

[0194] The altered signal peptide may comprise 1, 2, 3, 4 or 5 amino acid deletions or substitutions of hydrophobic amino acids. The hydrophobic amino acids may be substituted by non-hydrophobic amino acids, such as hydrophilic or neutral amino acids.

[0195] Nucleic acid construct

[0196] The present invention relates to a nucleic acid construct, which comprises: a first target nucleotide sequence (NOI1); a frame slip motif or a translation read-through motif (FSM / TRM); and a second target nucleotide sequence (NOI2).

[0197] The "nucleotide of interest" can be RNA or DNA. The nucleotide of interest (NOI) encodes a polypeptide of interest (POI) which can be all or part of a protein.

[0198] When transcribed and translated together, NOI1 and NOI2 (optionally together with subsequent NOI) can encode proteins. For example, when expressed in a cell, the nucleic acid construct can be capable of producing two products:

[0199] a) a first product encoded only by NOI1; and

[0200] b) A second product encoded by NOI1 and NOI2, which is produced when frame slippage or translational read-through occurs.

[0201] The relative expression level of the full-length product encoded by NOI1 and NOI2 may be less than the expression level of the truncated product encoded by NOI1 alone.

[0202] Alternatively, the nucleic acid construct may comprise one or more cleavage sites, such that the nucleotide sequence of interest is expressed as an independent protein.

[0203] The nucleic acid construct of the present invention can encode a polyprotein comprising a first and a second polypeptide. The polyprotein can be cleaved at a cleavage site to produce two separate polypeptides.

[0204] The NOI may encode an intracellular protein, a transmembrane protein, or a secreted protein.

[0205] The NOI may, for example, encode a chimeric antigen receptor (CAR) or a portion thereof, or a factor, such as a cytokine, that affects the activity of a CAR or a cell expressing a CAR.

[0206] The transgenic can encode the target antigen. In this regard, the technology can be used to produce a target antigen with varying and very low levels. These can be used in functional assays for, for example, T cells expressing CAR or engineered T cell receptors (TCR).

[0207] NOIs can encode proteins that participate in the synthesis of another entity in the cell. For example, cells can be induced to express the cancer antigen disialylganglioside (GD2) by transgenic expression of two enzymes, GM3 synthase and GD2 synthase (WO2015 / 132604). By reducing the expression level of these enzymes in cells, it is possible to produce GD2 低Target cells.

[0208] The NOI may encode a cytokine, such as a cytokine that enhances the inflammatory response and / or increases the efficacy of CAR-T cell therapy. The cytokine may be selected from the following: IL-7, IL-12, IL15, IL-17A, IL-18, and IL-21. In particular, the cytokine may be IL-12.

[0209] Interleukin 12 (IL-12) is an interleukin that is naturally produced by dendritic cells, macrophages, neutrophils, and human B lymphoblasts in response to antigenic stimulation. IL-12 is involved in the differentiation of naive T cells into Th1 cells. It is known as a T cell stimulating factor and can stimulate the growth and function of T cells. It stimulates the production of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) by T cells and natural killer (NK) cells, and reduces IL-4-mediated IFN-γ suppression.

[0210] IL-12 plays an important role in the activity of natural killer cells and T lymphocytes. IL-12 mediates the enhancement of the cytotoxic activity of NK cells and CD8+ cytotoxic T lymphocytes.

[0211] IL-12 is a potent immunomodulatory cytokine that is particularly useful for modulating the tumor microenvironment to redirect immune responses against cancer. However, IL-12 is systemically toxic, so methods for local production of IL-12 have attracted attention.

[0212] IL-12 is a heterodimeric cytokine encoded by two separate genes, IL-12A (p35) and IL-12B (p40). The active heterodimer (called "p70") is formed after protein synthesis.

[0213] The NOI may encode IL-12A and / or IL-12B. The sequence of human IL-12A is available from Uniprot Accession No. P29459. The portion of the sequence lacking the signal peptide is shown as SEQ ID No. 53. The sequence of human IL-12B is available from Uniprot Accession No. P29460. The portion of the sequence lacking the signal peptide is shown as SEQ ID No. 54.

[0214] SEQ ID No.53 (human IL-12A)

[0215] RNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEID HEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS

[0216] SEQ ID No.54 (human IL-12B)

[0217] WELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATL SAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPC

[0218] The NOI may encode "flexi-IL-12", which is a fusion between human IL-12α (p35) and IL-12β (p40) subunits, connected via a linker. A suitable flexi-IL-12 sequence is shown as SEQ ID No. 55.

[0219] SEQ ID No.55 (flexi-IL-12 sequence)

[0220]

[0221] In SEQ ID No. 55, the signal peptide is shown in bold, which is the signal peptide from mouse kappa chain V-III region MOPC 63 (Uniprot P01661); the serine-glycine linker is marked in bold and underlined.

[0222] The NOI may comprise one of the sequences shown in SEQ ID No. 53, 54 or 55 or a variant thereof. The variant sequence may have at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity with SEQ ID No. 53, 54 or 55, provided that the variant sequence retains IL-12 function when expressed in vivo. For example, the variant sequence may retain the ability to enhance cytotoxic T cell activity in vivo and / or the variant sequence may stimulate T cells to produce interferon-γ (IFN-γ).

[0223] The sequence encoding IL-12 or fliexi-IL12 can be placed downstream of the frame slip motif or translation read-through motif. This provides a way to control cytokine expression relative to CAR and reduce the level of cytokine expression.

[0224] The NOI may encode a chemokine, such as a chemokine that improves the efficacy of CAR-T cell therapy. The chemokine may be CCL19. In particular, the nucleic acid construct may co-express CCL19 and IL-7.

[0225] The NOI may encode an antibody or a portion thereof. For example, the NOI may encode an immunomodulatory antibody or antibody fragment. The antibody may block inhibitory signals (such as PD1) or activate the immune system (such as OX40 agonists, 41BB agonists, or ICOS agonists).

[0226] The transgene may encode a toxic compound such as botulinum toxin, diphtheria toxin, or Pseudomonas toxin.

[0227] Chimeric Antigen Receptor

[0228] The classic chimeric antigen receptor (CAR) is a chimeric type I transmembrane protein that connects the extracellular antigen recognition domain (conjugate) to the intracellular signaling domain (intracellular domain). The conjugate is typically a single-chain variable fragment (scFv) derived from a monoclonal antibody (mAb), but it can be based on other forms containing antibody-like antigen binding sites. The spacer domain is usually necessary to separate the conjugate from the membrane and allow it to be appropriately oriented. The common spacer domain used is the Fc of IgG1. Depending on the antigen, a more compact spacer can be satisfied, such as a stem from CD8α and even just an IgG1 hinge. The transmembrane domain anchors the protein in the cell membrane and connects the spacer to the intracellular domain.

[0229] Early CAR designs have intracellular domains derived from the intracellular portion of the γ chain of FcεR1 or CD3ζ. As a result, these first-generation receptors transmit immune signal 1, which is enough to trigger T cells to kill associated target cells, but cannot fully activate T cells to proliferate and survive. In order to overcome this limitation, a composite intracellular domain is constructed: the intracellular portion of the T cell co-stimulatory molecule is fused to the intracellular portion of CD3ζ, resulting in a second-generation receptor that can simultaneously transmit activation and co-stimulatory signals after antigen recognition. The most commonly used co-stimulatory domain is the co-stimulatory domain of CD28. This provides the most powerful co-stimulatory signal, i.e., immune signal 2, which triggers T cell proliferation. Some receptors have also been described, including TNF receptor family intracellular domains, such as closely related OX40 and 41BB, which transmit survival signals. Even more powerful third-generation CARs have now been described, which have intracellular domains capable of transmitting activation, proliferation, and survival signals.

[0230] When the CAR binds to the target antigen, this results in the transmission of an activation signal to the T cell on which it is expressed. The CAR thus directs the specificity and cytotoxicity of the T cell to the tumor cell expressing the targeted antigen.

[0231] Thus, a CAR generally comprises: (i) an antigen binding domain; (ii) a spacer; (iii) a transmembrane domain; and (iii) an intracellular domain that comprises or is associated with a signaling domain.

[0232] A CAR may have the following general structure:

[0233] Antigen binding domain-spacer domain-transmembrane domain-intracellular signaling domain (intracellular domain).

[0234] The NOI or combination of NOIs of the nucleic acid construct of the present invention may encode all or part of a CAR.

[0235] Functional read-through can be used to increase the functionality of the CAR. This can be achieved by inserting a translation read-through motif downstream of the antigen binding domain or between the signaling domains of the CAR ( Figure 3 F and F').

[0236] In some cases, secretion of the antigen binding domain (scFv / VHH) may be necessary to mitigate off-target effects, where CAR T cells target normal tissues that express low levels of the target antigen. The secreted antigen binding domain will bind to antigens expressed on the surface of normal cells, thereby preventing the CAR T cell from recognizing normal cells. By placing a translational read-through motif directly upstream of the CAR transmembrane domain, functional read-through can be used to engineer T cells to secrete the antigen binding domain.

[0237] A nucleic acid construct can have the general structure:

[0238] scFv / VHH-TRM-spacer-TM domain-intracellular domain, or

[0239] scFv / VHH-spacer-TRM-TM domain-intracellular domain

[0240] in:

[0241] scFv / VHH is a nucleotide sequence encoding the antigen binding domain

[0242] The spacer is a nucleotide sequence encoding the spacer

[0243] The TM domain is a nucleotide sequence encoding the TM domain, and

[0244] An intracellular domain is a nucleotide sequence encoding an intracellular domain, which may be, for example, a first generation, a second generation, or a third generation intracellular domain.

[0245] Functional read-through can also be used to generate a combination of first-generation, second-generation or third-generation CARs. In this case, the translation read-through motif can be placed between CD3z and the co-receptor intracellular domain, resulting in high expression levels of first-generation CARs (CD3ζ signaling domain alone) and significantly lower expression levels of second-generation or third-generation CARs.

[0246] A nucleic acid construct can have the general structure:

[0247] scFv / VHH-spacer-TM domain-CD3ζ intracellular domain TRM-costimulatory domain, or

[0248] scFv / VHH-spacer-TM domain-CD3ζ intracellular domain TRM1-costimulatory domain 1-TRM2-costimulatory domain 2

[0249] in:

[0250] scFv / VHH is a nucleotide sequence encoding the antigen binding domain

[0251] The spacer is a nucleotide sequence encoding the spacer

[0252] The TM domain is a nucleotide sequence encoding the TM domain, and

[0253] CD3ζ intracellular domain is a nucleotide sequence encoding the CD3ζ intracellular domain, and

[0254] A costimulatory domain is a nucleotide sequence encoding a costimulatory domain, for example from a co-receptor such as CD28 or from the intracellular domain of a member of the TNF receptor superfamily.

[0255] Different iterations can be generated by switching the positions of the CD3ζ and co-receptor intracellular domains such that engagement of the CAR will provide primarily a co-stimulatory signal to the cell (signal 2) and a reduced antigen signal to the cell (signal 1) because fewer CARs will have both the co-receptor and CD3ζ signaling domains.

[0256] Chimeric cytokine receptor

[0257] WO2017 / 029512 describes a chimeric cytokine receptor that transplants the binding specificity of a non-cytokine binding molecule onto the intracellular domain of a cytokine receptor. It also describes a chimeric transmembrane protein comprising a dimerization domain and a cytokine receptor intracellular domain.

[0258] Dimerization may occur spontaneously, in which case the chimeric transmembrane protein will be constitutively active. Alternatively, dimerization may occur only in the presence of a chemical inducer of dimerization (CID), in which case the transmembrane protein causes cytokine-type signaling only in the presence of the CID.

[0259] The constitutively active chimeric cytokine receptor may comprise a Fab portion of an antibody as an extracellular domain. In this regard, the dimerization domain may comprise a dimerization portion of a heavy chain constant domain (CH) and a light chain constant domain (CL).

[0260] A chimeric transmembrane protein may comprise two polypeptides:

[0261] (i) a first polypeptide comprising:

[0262] (a) a first dimerization domain; and

[0263] (b) the first chain of the intracellular domain of a cytokine receptor; and

[0264] (ii) a second polypeptide comprising:

[0265] (a) a second dimerization domain that dimerizes together with the first dimerization domain; and

[0266] (b) Second chain of the intracellular domain of the cytokine receptor.

[0267] In particular, the chimeric transmembrane protein may comprise:

[0268] (i) a first polypeptide comprising:

[0269] (a) Heavy chain constant domain (CH)

[0270] (b) the first chain of the intracellular domain of a cytokine receptor; and

[0271] (ii) a second polypeptide comprising:

[0272] (a) Light chain constant domain (CL)

[0273] (b) Second chain of the intracellular domain of the cytokine receptor.

[0274] The first chain and the second chain of the cytokine receptor intracellular domain may be selected from the group consisting of the α chain, β chain and γ chain of the type I cytokine receptor intracellular domain.

[0275] The cytokine receptor intracellular domain may comprise:

[0276] (i) IL-2 receptor β chain intracellular domain

[0277] (ii) IL-7 receptor α chain intracellular domain; or

[0278] (iii) IL-15 receptor α chain intracellular domain; and / or

[0279] (iv) Common γ chain receptor intracellular domain.

[0280] IL-2

[0281] IL-2 binds to the IL-2 receptor, which has three forms produced by different combinations of three different proteins, often called "chains": alpha, beta, and gamma; these subunits are also part of other cytokine receptors. The beta and gamma chains of IL-2R are members of the type I cytokine receptor family.

[0282] These three receptor chains are separately and differentially expressed on various cell types and can be assembled in different combinations and orders to produce low-, intermediate- and high-affinity IL-2 receptors.

[0283] The α chain binds IL-2 with low affinity, the β and γ chains combine to form a complex that binds IL-2 with intermediate affinity (mainly on memory T cells and NK cells); and all three receptor chains form a complex on activated T cells and regulatory T cells that binds IL-2 with high affinity (Kd ~ 10-11M).

[0284] Three IL-2 receptor chains span the cell membrane and extend into the cell, delivering biochemical signals to the interior of the cell. The alpha chain is not involved in signaling, but the beta chain is complexed with the tyrosine phosphatase JAK1. Similarly, the gamma chain is complexed with another tyrosine kinase called JAK3. These enzymes are activated by IL-2 binding to the external domain of IL-2R.

[0285] When naive T cells are also stimulated by antigen, IL-2 signaling promotes T cell differentiation into effector T cells and memory T cells. Through their role in the formation of T cell immune memory, which depends on the expansion of the number and function of antigen-selected T cell clones, they also play a key role in long-term cell-mediated immunity.

[0286] The chimeric cytokine receptors of the invention may comprise the IL-2 receptor beta chain and / or the IL-2 receptor (ie, shared) gamma chain.

[0287] The amino acid sequences of the intracellular domains of the IL-2 β chain and the common γ chain are shown as SEQ ID Nos. 56 and 57.

[0288] SEQ ID No.56: Intracellular domain derived from human common gamma chain:

[0289] ERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAPPCYTLKPET

[0290] SEQ ID No.57: Intracellular domain derived from human IL-2Rβ:

[0291] NCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFTNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPL QPLSGEDDAYCTFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVPDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQELQGQDPTHLV

[0292] The term "derived from" means that the intracellular domain of the chimeric cytokine receptor of the present invention has the same sequence as the wild-type sequence of the endogenous molecule or a variant thereof, which variant retains the ability to form a complex with JAK-1 or JAK-3 and activate one of the above signal transduction pathways.

[0293] A "variant" sequence has at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a wild-type sequence (e.g., SEQ ID No. 56 or 57), provided that the variant sequence retains the function of the wild-type sequence, i.e., retains the ability to form a complex with JAK-1 or JAK-3 and activate, for example, the JAK-STAT signaling pathway.

[0294] The percent identity between two polypeptide sequences can be readily determined using programs such as BLAST, which is freely available from http: / / blast.ncbi.nlm.nih.gov.

[0295] Constant region domain

[0296] There are two types of light chains in humans: kappa chains and lambda chains. The lambda class has four subclasses: lambda 1, lambda 2, lambda 3, and lambda 4. The light chain constant region of the Fab-type chimeric receptor may be derived from any of these light chain types.

[0297] The light chain constant domain of the chimeric cytokine receptor may have a sequence as shown in SEQ ID NO. 58, which is a kappa chain constant domain.

[0298] SEQ ID No.58

[0299] TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT KSFNRGEC

[0300] There are five types of mammalian immunoglobulin heavy chains: γ, δ, α, μ and ε, which define the classes of immunoglobulins IgG, IgD, IgA, IgM and IgE, respectively. Heavy chains γ, δ and α have a constant domain consisting of three tandem Ig domains and a hinge for increased flexibility. Heavy chains μ and ε are composed of four domains.

[0301] The CH domain of the chimeric cytokine receptor of the present invention may comprise a sequence as shown in SEQ ID No. 59, which is derived from a gamma immunoglobulin heavy chain.

[0302] SEQ ID No.59

[0303] STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV

[0304] In a preferred embodiment, the present invention provides a nucleic acid construct comprising: a first nucleotide sequence encoding a chimeric antigen receptor (CAR); a frame slipping motif (FSM) or a translation read-through motif (TRM); and a second nucleotide sequence encoding a chimeric cytokine receptor (CCR).

[0305] Cleavage site

[0306] The nucleic acid construct of the first aspect of the invention may comprise a sequence encoding a cleavage site located between the nucleic acid sequences encoding the first and second polypeptides, thereby allowing the first and second polypeptides to be expressed as separate entities.

[0307] The cleavage site may be any sequence capable of separating the polypeptides comprising the first and second polypeptides.

[0308] The term "cleavage" is used herein for convenience, but the cleavage site can separate the first and second polypeptides into separate entities by mechanisms other than classical cleavage. For example, for the foot-and-mouth disease virus (FMDV) 2A self-cleavage peptide (see below), various models have been proposed to explain the "cleavage" activity: proteolysis by host cell proteases, autoproteolysis or translation effects (Donnelly et al (2001) J. Gen. Virol. 82: 1027-1041). As long as the cleavage site between the nucleic acid sequences encoding the first and second polypeptides results in the expression of the first and second polypeptides as separate entities, the exact mechanism of such "cleavage" is not important for the purposes of the present invention.

[0309] The cleavage site may be a furin cleavage site.

[0310] Furin is an enzyme belonging to the subtilisin-like proprotein convertase family. The members of this family are proprotein convertases that process potential precursor proteins into their biologically active products. Furin is a calcium-dependent serine endoprotease that can effectively cut precursor proteins at the basic amino acid processing sites they pair. Examples of furin substrates include proparathyroid hormone, transforming growth factor β1 precursor, proalbumin, pro-β-secretase, membrane type 1 matrix metalloproteinase, β subunit of nerve growth factor progenitor, and Willebrand factor. Furin cuts proteins just downstream of the basic amino acid target sequence (typically Arg-X-(Arg / Lys)-Arg' (SEQ ID No.50)) and is enriched in the Golgi apparatus.

[0311] The cleavage site may be a tobacco etch virus (TEV) cleavage site.

[0312] TEV protease is a highly sequence-specific cysteine ​​protease, which is a chymotrypsin-like protease. It is very specific to its target cleavage site and is therefore often used for controlled cleavage of fusion proteins in vitro and in vivo. The common TEV cleavage site is ENLYFQ\S (SEQ ID No.51) (wherein "\" represents the peptide bond that is cleaved). Mammalian cells such as human cells do not express TEV protease. Therefore, in embodiments in which the present nucleic acid construct comprises a TEV cleavage site and is expressed in mammalian cells, exogenous TEV protease must also be expressed in mammalian cells.

[0313] The cleavage site may encode a self-cleaving peptide.

[0314] "Self-cleaving peptide" refers to a peptide that functions such that when a polypeptide comprising a first and a second polypeptide and the self-cleaving peptide is produced, it is immediately "cleaved" or separated into different and discrete first and second polypeptides without the need for any external cleavage activity.

[0315] The self-cleaving peptide can be a 2A self-cleaving peptide from foot-and-mouth virus or cardiovirus. The major 2A / 2B cleavage of foot-and-mouth virus and cardiovirus is mediated by 2A "cleaved" at its own C-terminus. In foot-and-mouth viruses such as foot-and-mouth disease virus (FMDV) and equine rhinitis type A virus, the 2A region is a short segment of about 18 amino acids, which together with the N-terminal residue (conserved proline residue) of protein 2B represents an autonomous element capable of mediating "cleavage" at its own C-terminus.

[0316] The C-terminal 19 amino acids of the longer cardiovirus protein, together with the N-terminal proline of 2B, mediate "cleavage" with an efficiency approximately equivalent to that of the foot-and-mouth virus FMDV 2a sequence. Cardioviruses include encephalomyocarditis virus (EMCV) and Theilerian murine encephalitis virus (TMEV).

[0317] Mutational analysis of EMCV and FMDV 2A showed that the motif DxExNPGP (SEQ ID No. 52) is closely associated with the "cleavage" activity (Donelly et al (2001) as mentioned above).

[0318] The cleavage site of the present invention may comprise the following amino acid sequence:

[0319] Dx1Ex2NPGP, wherein x1 and x2 are any amino acids. X1 can be selected from the following group: I, V, M and SX2. X2 can be selected from the following group: T, M, S, L, E, Q and F.

[0320] For example, the cleavage site may comprise one of the amino acid sequences shown in Table 2.

[0321] Table 2

[0322]

[0323]

[0324] The cleavage site based on the 2A sequence may be, for example, 15 to 22 amino acids in length. The sequence may comprise the C-terminus of the 2A protein followed by a proline residue (which corresponds to the N-terminal proline of 2B).

[0325] Mutation studies have also shown that certain variants other than the naturally occurring 2A sequence are also active. The cleavage site may correspond to a variant sequence of the naturally occurring 2A polypeptide, the mutant sequence having one, two or three amino acid substitutions that retains the ability to induce the "cleavage" of the polyprotein sequence into two or more separate proteins.

[0326] The cleavage sequence may be selected from the following sequences, all of which have been shown to have some degree of activity (Donnelly et al (2001), supra):

[0327] LLNFDLLKLAGDVESNPGP(SEQ ID No.18)

[0328] LLNFDLLKLAGDVQSNPGP(SEQ ID No.19)

[0329] LLNFDLLKLAGDVEINPGP(SEQ ID No.20)

[0330] LLNFDLLKLAGDVEFNPGP(SEQ ID No.21)

[0331] LLNFDLLKLAGDVESHPGP(SEQ ID No.22)

[0332] LLNFDLLKLAGDVESEPGP(SEQ ID No.23)

[0333] LLNFDLLKLAGDVESQPGP(SEQ ID No.24)

[0334] LLNFDLLKLAGDVESNPGG(SEQ ID No.25)

[0335] Based on the sequence of the DxExNPGP motif, "2A-like" sequences have been found in picornaviruses other than foot-and-mouth virus or cardiovirus, "picornavirus-like" insect viruses, type C rotaviruses, repetitive sequences in Trypanosoma species, and bacterial sequences (Donnelly et al (2001), supra). The cleavage site may comprise one of these 2A-like sequences, for example:

[0336] YHADYYKQRLIHDVEMNPGP(SEQ ID No.26)

[0337] HYAGYFADLLIHDIETNPGP(SEQ ID No.27)

[0338] QCTNYALLKLAGDVESNPGP(SEQ ID No.28)

[0339] ATNFSLLKQAGDVEENPGP(SEQ ID No.29)

[0340] AARQMLLLLSGDVETNPGP(SEQ ID No.30)

[0341] RAEGRGSLLTCGDVEENPGP(SEQ ID No.31)

[0342] TRAEIEDELIRAGIESNPGP(SEQ ID No.32)

[0343] TRAEIEDELIRADIESNPGP(SEQ ID No.33)

[0344] AKFQIDKILISGDVELNPGP(SEQ ID No.34)

[0345] SSIIRTKMLVSGDVEENPGP(SEQ ID No.35)

[0346] CDAQRQKLLLSGDIEQNPGP(SEQ ID No.36)

[0347] YPIDFGGFLVKADSEFNPGP(SEQ ID No.37)

[0348] The cleavage site may comprise a 2A-like sequence as shown in SEQ ID No. 31 (RAEGRGSLLTCGDVEENPGP).

[0349] It has been shown that N-terminal "extensions" comprising 5 to 39 amino acids can increase activity (Donnelly et al (2001), supra). In particular, the cleavage sequence may comprise one of the following sequences or a variant thereof having, for example, up to 5 amino acid changes which retains cleavage site activity:

[0350] VTELLYRMKRAETYCPRPLAIHPTEARHKQKIVAPVKQTLNFDLLKLAGDVESNPGP(SEQ IDNo.38)

[0351] LLAIHPTEARHKQKIVAPVKQTLNFDLLKLAGDVESNPGP(SEQ ID No.39)

[0352] EARHKQKIVAPVKQTLNFDLLKLAGDVESNPGP(SEQ ID No.40)

[0353] APVKQTLNFDLLKLAGDVESNPGP(SEQ ID No.41)

[0354] Carrier

[0355] The present invention also provides a vector comprising the nucleic acid construct according to the first aspect of the present invention.

[0356] Such vectors can be used to introduce the nucleic acid construct into a host cell, thereby causing it to express the first and second polypeptides.

[0357] The vector may for example be a plasmid or a viral vector, such as a retroviral vector or a lentiviral vector, or a transposon-based vector or a synthetic mRNA.

[0358] The vector may be capable of transfecting or transducing a mammalian cell, such as a T cell or a target cell.

[0359] cell

[0360] The present invention further provides a cell comprising a nucleic acid construct or vector of the present invention expressing a first and a second polypeptide encoded by the nucleic acid sequences.

[0361] The cell may be any eukaryotic cell, such as an immune cell.

[0362] The cell may be a cytolytic immune cell, such as a T cell or a natural killer cell.

[0363] When the transgene expresses a target antigen, the cell can be a target cell for a T cell or a CAR-T cell.

[0364] method

[0365] In another aspect, the present invention provides a method for preparing a cell according to the present invention, comprising the step of introducing the nucleic acid construct or vector of the present invention into a cell.

[0366] The nucleic acid construct can be introduced by transduction or transfection.

[0367] The cell can be a cell isolated from a subject, for example, a T cell or a NK cell isolated from a subject.

[0368] The present invention also provides a method for regulating the relative expression of two transgenes in a nucleic acid construct, the method comprising the following steps: introducing a frame slip motif or a translation read-through motif between the two transgenes to reduce the expression of the downstream transgene.

[0369] The nucleic acid construct may comprise a sequence encoding a cleavage site located between the two transgenes. The relative expression of the two transgenes may be adjusted by selecting different frame-slip motifs or translational read-through motifs and / or by mutating the sequences immediately 5' and / or 3' to the motifs.

[0370] The present invention also provides a method for regulating the relative expression of two transgenes in a nucleic acid construct, the method comprising the following steps: introducing a frame slip motif or a translation read-through motif between the two transgenes to reduce the expression of the downstream transgene.

[0371] The frame-slipping motif or translation read-through motif may be as described in the preceding aspects of the invention.

[0372] The present invention will now be further described by way of examples, which are intended to help those skilled in the art to practice the present invention and are not intended to limit the scope of the present invention in any way. Example

[0373] Example 1 - Preparation and testing of frame-slip constructs

[0374] The following constructs were transduced into SupT1 cells.

[0375] ·SFGmR.RQR8-2A-SKIP_7xU-CD22ecto-CD19tm-dCD19endo

[0376] SFGmR.RQR8-2A-SKIP_6xU-CD22ecto-CD19tm-dCD19endo (control)

[0377] The construct encodes RQR8, a sorting-suicide transmembrane protein described in WO2013 / 153391, and a chimeric protein having the extracellular domain of CD22 and the transmembrane and intracellular domains of CD19.

[0378] The first construct contained a transcription frame slipping motif with seven thymine bases (uracil in mRNA) that facilitates transcription slipping and base loss from mRNA, placing the CD22 coding sequence in frame and resulting in the expression of a CD22-CD19 chimera.

[0379] Flow cytometric analysis showed that the introduction of the frame-slipping motif resulted in a significant decrease in the expression of CD22-CD19 chimeras, while similar levels of the RQR8 sorting marker ( Figure 2 C).

[0380] Example 2 - Preparation and testing of translational read-through constructs

[0381] Two translational read-through motifs, STOP-CUAG and STOP-CAAUUA, were shown to function in human T cells (SupT1) and human B cells (Raji) and support translational read-through of downstream self-cleaving 2A peptide sequences and transgene coding sequences (CD22 and BCMA).

[0382] To test the functionality of these read-through motifs in combination with different stop codons, the following constructs were transduced into HEK293T cells.

[0383] Read-through motif STOP-CUAG

[0384] ·SFGmR.RQR8-STOP-TGACTAG-2A-hCD22ecto-CD19TM-dCD19endo

[0385] ·SFGmR.RQR8-STOP-TAGCTAG-2A-hCD22ecto-CD19TM-dCD19endo

[0386] ·SFGmR.RQR8-STOP-TAACTAG-2A-hCD22ecto-CD19TM-dCD19endo

[0387] ·SFGmR.RQR8-NO_STOP_TGGCTAG-T2A-hCD22ecto-CD19TM-dCD19endo

[0388] Read-through motif STOP-CAAUUA

[0389] ·SFGmR.RQR8-STOP-TGACAATTA-2A-hCD22ecto-CD19TM-dCD19endo

[0390] ·SFGmR.RQR8-STOP-TAGCAATTA-2A-hCD22ecto-CD19TM-dCD19endo

[0391] ·SFGmR.RQR8-STOP-TAACAATTA-2A-hCD22ecto-CD19TM-dCD19endo

[0392] ·SFGmR.RQR8_NO_STOP_TGGCAATTA-T2A-hCD22-CD19TM-dCD19endo

[0393] Signal peptide mutant

[0394] ·SFGmR.RQR8-2A-Signal peptide K9-hCD22ecto-CD19TM-dCD19endo

[0395] ·SFGmR.RQR8-2A-Signal peptide K10-hCD22ecto-CD19TM-dCD19endo

[0396] ·SFGmR.RQR8-2A-Signal peptide K11-hCD22ecto-CD19TM-dCD19endo

[0397] The wild-type signal peptide sequence and the sequences of the altered signal peptides K19, K10 and K11 are shown below as SEQ ID Nos. 42 to 45.

[0398] SEQ ID No.42-Rat Igκ chain V-III region signal peptide (wild type)

[0399] METDTLILWVLLLLVPGSTG

[0400] SEQ ID No.43-Rat Igκ chain V-III region signal peptide (K9 mutant)

[0401] METDTLILKVLLLLVPGSTG

[0402] SEQ ID No.44-Rat Igκ chain V-III region signal peptide (K10 mutant)

[0403] METDTLILWKLLLLVPGSTG

[0404] SEQ ID No.45-Rat Igκ chain V-III region signal peptide (K11 mutant)

[0405] METDTLILWVKLLLVPGSTG

[0406] The expression of CD22-CD19 chimeras was analyzed by flow cytometry, and the results are shown in Figure 4A. Expression of the CD22-CD19 chimera was reduced in the lysine 11 signal peptide mutant (L11K mutation) compared to the wild-type signal peptide. When the stop-CUAG and stop-CAAUUA translation read-through motifs were placed 5' of the CD22-CD19 transgene, they produced similar results, with both motifs reducing the expression level of the chimera to approximately 2% or less of the RQR8 sorting marker. Even lower CD22-CD19 chimera expression levels were obtained using a double stop codon translation read-through motif (row 4).

[0407] The mean fluorescence intensity of CD22-CD19 chimeras on the surface of transfected HEK293T cells was quantified and the results are shown in Figure 4B Substantially lower levels of CD22-CD19 chimeras were obtained using the translational read-through construct compared to the attenuated signal peptide mutant.

[0408] Example 3 - Functional translation read-through: Secretion of soluble anti-CD22 Fab

[0409] A nucleic acid construct encoding the RQR8 sorting marker followed by a 2A self-cleaving peptide sequence and an anti-CD22 CAR with CL and CH1 spacers was designed to produce a soluble Fab fragment as follows:

[0410] ·SFGmR.RQR8-2A-aCD22_FabCAR_9A8-1-STOP_SKIP_TAG-41BBz

[0411] ·SFGmR.RQR8-2A-aCD22_FabCAR_9A8-1-STOP_SKIP_TAA-41BBz

[0412] ·SFGmR.RQR8-2A-aCD22_FabCAR_9A8-1-STOP_SKIP_TGA-41BBz

[0413] These constructs were transduced into PBMCs and cytotoxicity assays were performed using target cells expressing low or high levels of CD22 to determine the efficacy of the CAR. This mimics the situation where low levels of target antigen are expressed on normal tissues and the cytotoxic response needs to be fine-tuned to prevent CAR T cells from targeting these cells.

[0414] Example 4 - Functional translation read-through: Switching from first generation to second or third generation CAR

[0415] To investigate whether functional translational read-through could be used to switch between first- and second-generation CARs, the following constructs were generated:

[0416] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta

[0417] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TAA-41BB

[0418] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TGA-41BB

[0419] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-NO_STOP_SKIP_TCA-41BB

[0420] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TAG-41BB

[0421] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TAA-CD28

[0422] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TAG-CD28

[0423] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-NO_STOP_SKIP_TCA-CD28

[0424] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TGA-CD28

[0425] This first set of constructs expressed the sorting marker RQR8 and a first generation anti-CD19 CAR with an Fc spacer domain and a CD3ζ intracellular domain, followed by a translation read-through motif and a 4-1BB or CD28 co-stimulatory intracellular domain. Re-stimulation assays were set up using transduced PBMCs, which were cultured in plates coated with anti-Fc antibodies that bind to the spacer domain of the CAR and trigger proliferation. The control first generation CAR with only CD3ζ showed limited proliferation, while the other CARs proliferated extensively due to the presence of co-stimulatory signals.

[0426] A second set of constructs was generated, similar to the first, as follows:

[0427] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-41BB-STOP_SKIP_TAA-Zeta

[0428] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-41BB-STOP_SKIP_TGA-Zeta

[0429] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-41BB-NO_STOP_SKIP_TCA-Zeta

[0430] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-41BB-STOP_SKIP_TAG-Zeta

[0431] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-CD28-STOP_SKIP_TAA-Zeta

[0432] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-CD28-STOP_SKIP_TGA-Zeta

[0433] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-CD28-NO_STOP_SKIP_TCA-Zeta

[0434] ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-CD28-STOP_SKIP_TAG-Zeta

[0435] In these constructs, the costimulatory domain from 4-1BB or CD28 is located before the translation read-through motif, and the CD3ζ intracellular domain is placed after the translation read-through motif. Cytotoxicity assays and proliferation assays are established using PBMCs transduced with these constructs. The translation read-through of these constructs is necessary for producing functional CAR (i.e., CAR with intracellular signaling domain).

[0436] Example 5 - Preparation and testing of composite read-through motifs

[0437] In order to reduce the expression of the multiple transgene expression cassette to very low levels, a construct with two stop codon (STOP)-translation read-through motifs was designed as follows:

[0438] Marker (RQR8 or HA8)-STOP_readthrough motif-2A-GD3 synthase-STOP_readthrough motif-2A-GD2 synthase

[0439] The ganglioside GD2 is synthesized by two enzymes, GD2 synthase and GD3 synthase. The above constructs resulted in reduced expression of GD3 synthase, and even lower expression of GD2 synthase compared to the marker gene.

[0440] Example 6 - Preparation and testing of universal read-through constructs

[0441] To overcome the problem of background-dependent expression from read-through motifs, a set of universal constructs were generated into which the second transgene could be cloned and expressed at defined levels. The universal constructs consisted of a self-cleaving 2A peptide sequence followed by a stop codon and a read-through motif and a second self-cleaving peptide sequence. The presence of a self-cleaving peptide sequence flanking the stop codon read-through motif reduced the effects of background dependence on translation read-through and resulted in consistent and predictable transgene expression levels.

[0442] The tested constructs are as follows:

[0443] Read-through motif STOP CUAG

[0444] · Marker-2A-transgenic 1-2A-UGA-CUAG-2A-transgenic 2

[0445] · Marker-2A-transgenic 1-2A-UAG-CUAG-2A-transgenic 2

[0446] · Marker-2A-transgenic 1-2A-UAA-CUAG-2A-transgenic 2

[0447] Read-through motif STOP CAAUUA

[0448] · Marker-2A-transgenic 1-2A-UGA-CAAUUA-2A-transgenic 2

[0449] · Marker-2A-transgenic 1-2A-UAG-CAAUUA-2A-transgenic 2

[0450] · Marker-2A-transgenic 1-2A-UAA-CAAUUA-2A-transgenic 2

[0451] Example 7 - Ultra-low expression achieved by placing translation read-through motifs in tandem

[0452] To determine whether it was possible to obtain ultra-low levels of transgene expression, a construct was generated with two translational read-through motifs placed in tandem in a tricistronic cassette ( Figure 5A). The first transgene in the cassette is always a cell surface marker, consisting of an HA epitope presented on the CD8a stalk, which is used to identify transduced cells, followed by a stop codon, a translation read-through motif, and a self-cleaving peptide sequence. The second transgene in the expression cassette is one of two fluorescent proteins, Clover3 (green fluorescent protein) or enhanced blue fluorescent protein (EBFP) in series, followed by a stop codon, a translation read-through motif, and a self-cleaving peptide sequence. The third transgene in the expression cassette is an alternative fluorescent protein. By placing the stop codon and the translation read-through motif in series, the expression level of the fluorescent protein at the third position should be lower than the expression level at the second position.

[0453] Peripheral blood mononuclear cells (PBMCs) were transduced with this construct, and flow cytometry was performed to quantify the expression level of the fluorescent protein relative to the cell surface marker. The results of these experiments showed that the expression level of the fluorescent protein at the third position downstream of the two stop codons and the translation read-through motif was significantly lower than that at the second position ( Figure 5 B). Consistent with previous experiments, the level of translation read-through depends on the stop codon, with the order of stop codon stringency being UAA>UAG>UGA. In the case of tandem Clover3, expression levels were reduced 33-fold in the presence of UAA, 24-fold in the presence of UAG, and 6-fold in the presence of UGA compared to the control without a stop codon. When placed in the third position, tandem Clover3 expression levels were reduced >100-fold for all three stop codons ( Figure 5 C).

[0454] Example 8 - Control of IL-12 secretion by translation read-through

[0455] IL-12 is a potent proinflammatory cytokine secreted by phagocytes and dendritic cells in response to pathogens, signals from T cells and natural killer (NK) cells, and components of the inflammatory extracellular matrix. The primary target of IL-12 is cytotoxic T cells, T H 1 helper T cells and NK cells, which express IL-12 receptors on their cell surfaces. In response to IL-12, T H 1 Helper T cells release IFNγ and TNFα.

[0456] CAR-T cells have been engineered to express IL-12 either constitutively or from an inducible promoter, which has been shown to improve the efficacy of CAR-T cell therapy when targeting solid tumors. Systemic administration of IL-12 is toxic, and to address this issue, CAR T cells or other immune cells have been engineered to release IL-12 into the tumor microenvironment. However, genetically modified T cell IL-12 secretion can result in highly toxic systemic levels of the cytokine.

[0457] We designed a construct in which a fusion between the human IL-12α (p35) and IL-12β (p40) subunits flexi-IL-12 was cloned downstream of the sorting marker RQR8 and a self-cleaving peptide sequence. A stop codon or control sequence (UGG encoding tryptophan) and a translation read-through sequence CAAUUA were placed immediately downstream of the RQR8 coding sequence ( Figure 6 A). PBMCs were transduced with the construct and stained with antibodies against CD3ε and RQR8 to determine transduction efficiency and verify the presence of the transgene ( Figure 6 B). After determining the transduction efficiency, PBMCs were returned to culture and supernatants were collected at 24, 48, and 72 hours and analyzed by high-sensitivity ELISA for the presence of IL-12 ( Figure 6 C). The data show that inclusion of a stop codon and a translation read-through motif reduced expression levels by more than 40-fold ( Figure 6 C). There is a trend in the stop codon stringency hierarchy, with the order from most stringent to least stringent being UAA>UAG>UGA. These data suggest that it is possible to significantly reduce the level of IL-12 secretion from transduced cells.

[0458] To demonstrate that secreted levels of flexi-IL-12 are able to trigger an immune response, we generated another set of constructs. These constructs were tricistronic constructs containing a suicide gene (RapaCasp9), the murine cell surface marker Thy1.1, and murine flexi-IL-12 ( Figure 7 A). The murine flexi-IL-12 sequence was placed at the end of a tricistronic cassette and a self-cleaving peptide sequence was used to promote expression of the polypeptide. The translation read-through construct (UAA-CAAUUA) was compared to a construct containing murine flexi-IL-12 with an attenuated signal peptide sequence and another construct that utilized an internal ribosome entry site (IRES) to control cytokine expression. Splenocytes obtained from BalbC mice were transduced with the constructs and flow cytometry was performed using antibodies against CD3 and the cell surface marker Thy1.1 to determine transduction efficiency ( Figure 7 B). After determining the transduction efficiency, splenocytes were returned to culture and supernatants were collected at 24, 48 and 72 hours and analyzed by ELISA for the presence of murine IL-12 ( Figure 7 C). The results showed that the expression of IL-12 from IRES was reduced by about 3-fold. In contrast, the expression of IL-12 from the translation read-through motif UAA-CAAUUA was reduced to the point where it could no longer be detected by ELISA ( Figure 7C). To determine whether IL-12 was present in the culture medium, the supernatant was recovered and used to restimulate activated splenocytes. The supernatants of these restimulated splenocytes were analyzed for the presence of IFNγ, since IFNγ is secreted by T cells and NK cells stimulated with IL-12 ( Figure 7 D). IFNγ was detected in all supernatants harvested from restimulated splenocytes. According to the results of the IL-12 ELISA, the highest levels of IFNγ secretion were observed from splenocytes restimulated with supernatants from control or IRES-transduced splenocytes. Importantly, IFNγ secretion was observed from splenocytes restimulated with supernatants from splenocytes transduced with the translation read-through construct ( Figure 7 D) These results suggest that it is possible to obtain significantly reduced levels of IL-12 secretion from transduced cells, thereby potentially mitigating the toxic effects of this potent cytokine while still maintaining therapeutic benefit.

[0459] To demonstrate the efficacy and safety of IL-12 secretion from translational read-through constructs in a more therapeutic setting, splenocytes were co-transduced with constructs encoding truncated murine CD34, anti-GD2 chimeric antigen receptor, and firefly luciferase and the cytokine expression constructs described above. Transduced splenocytes were stained with antibodies against CD34 and Thy1.1 and analyzed by flow cytometry to determine transduction efficiency ( Figure 8 A). Mice were injected with 5x10 6 The mice were sacrificed 15 days later and their spleens were removed. Comparison of spleen size showed that splenomegaly was observed only in the case of constitutive expression of IL-12 (2A), while spleen sizes in the other groups were comparable to those in the control group ( Figure 8 B) To investigate in more detail the cell types recruited to the spleens of injected mice, splenocytes were stained with antibodies against CD11b, CD3, CD4, CD8, and CD19 and analyzed by flow cytometry ( Fig. 9 A). The results showed that macrophages (CD11b + ) were recruited to the spleen of mice injected with splenocytes transduced with constitutively expressed IL-12, of which approximately 20% were CD11b + Consistent with previous ELISA data showing that the IRES construct produced higher levels of IL-12 than the translational read-through construct, more CD11b was present in the spleens of mice injected with these cells. + cell( Fig. 9 B) CD4 T cells were observed in mice injected with splenocytes. + and CD8 + Increased recruitment of splenocytes transduced with a construct constitutively expressing IL-12 or a construct derived from IRES ( Fig. 9C, D, and E). In contrast, CD11b in the spleen of mice injected with splenocytes transduced with the translational read-through construct + and CD3 + Cell numbers were comparable to those of controls. A reduction in B cell numbers was observed only in the spleens of mice injected with splenocytes constitutively expressing IL-12. Together, these results suggest that in the absence of antigen, expression of IL-12 from a translational read-through construct does not induce any toxicity or recruitment of immune cells.

[0460] All publications mentioned in the above specification are incorporated herein by reference. Without departing from the scope and spirit of the present invention, various modifications and variations of the described method and system of the present invention will be apparent to those skilled in the art. Although the present invention has been described in conjunction with specific preferred embodiments, it should be understood that the claimed invention should not be unduly limited to such specific embodiments. In fact, it is apparent to those skilled in the art of molecular biology or related fields that various modifications described for implementing the present invention are intended to fall within the scope of the appended claims.

Claims

1. A nucleic acid construct comprising: a first target nucleotide sequence (NOI1); a translation read-through motif (TRM); and a second target nucleotide sequence (NOI2), wherein the nucleic acid construct is capable of producing two products when expressed in a cell: a) a first product encoded only by NOI1; and b) A second product encoded by NOI1 and NOI2, which is produced when translation read-through occurs.

2. The nucleic acid construct according to claim 1, comprising a translation read-through motif (TRM), the translation read-through motif comprising the sequence STOP-CUAG or STOP-CAAUUA, wherein "STOP" is a stop codon.

3. The nucleic acid construct according to claim 2, wherein the translation read-through motif comprises one of the following sequences: UGA-CUAG (SEQ ID No. 5) UAG-CUAG (SEQ ID No. 6) UAA-CUAG (SEQ ID No. 7) UGA-CAAUUA (SEQ ID No. 8) UAG-CAAUUA (SEQ ID No. 9) UAA-CAAUUA (SEQ ID No. 10).

4. A nucleic acid construct according to any one of the preceding claims, wherein the second product is a chimeric antigen receptor (CAR) and the first product is a truncated form of the CAR that is unable to induce CAR-mediated cell signaling.

5. The nucleic acid construct of claim 4, wherein the first product is a chimeric antigen receptor (CAR) comprising an intracellular signaling domain, and the second product is a CAR comprising an intracellular signaling domain and one or more co-stimulatory domains.

6. A vector comprising the nucleic acid construct according to any one of the preceding claims.

7. A retroviral vector or a lentiviral vector according to claim 6.

8. A cell comprising the nucleic acid construct according to any one of claims 1 to 5 or the vector according to claim 6 or 7.

9. A method for preparing the cell according to claim 8, comprising the step of introducing the nucleic acid construct according to any one of claims 1 to 5 or the vector according to claim 6 or 7 into the cell.